Adinolfi Luigi Elio, Jacobson Ira, Bondin Mark, Cacoub Patrice
Department of Medical, Surgical, Neurological, Metabolic, and Geriatric Sciences, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy.
NYU Langone Health, New York, NY, USA.
Antivir Ther. 2018;23(Suppl 2):11-21. doi: 10.3851/IMP3255.
Type 2 diabetes mellitus (T2DM) has been identified as an extrahepatic manifestation of chronic HCV infection. Conversely, in the context of chronic HCV infection, T2DM can accelerate the course of HCV-induced liver disease leading to increased risk of fibrosis, cirrhosis and hepatocellular carcinoma. The presence of T2DM negatively impacts the efficacy of interferon-based antiviral therapy, but real-world data with high-efficacy direct-acting antiviral therapies suggest high viral clearance rates in T2DM patients. In HCV-infected individuals, viral eradication is associated with a reduced risk of de novo T2DM in non-diabetic patients and beneficial metabolic changes in patients with T2DM, highlighting the importance of antiviral treatment and physician awareness of this association.
2型糖尿病（T2DM）已被确认为慢性丙型肝炎病毒（HCV）感染的肝外表现。相反，在慢性HCV感染的情况下，T2DM会加速HCV诱导的肝病进程，导致纤维化、肝硬化和肝细胞癌的风险增加。T2DM的存在会对基于干扰素的抗病毒治疗效果产生负面影响，但高效直接抗病毒治疗的真实世界数据表明，T2DM患者的病毒清除率很高。在HCV感染个体中，病毒根除与非糖尿病患者新发T2DM风险降低以及T2DM患者有益的代谢变化相关，这突出了抗病毒治疗的重要性以及医生对这种关联的认识。
